肝癌介入治疗对多药耐药相关蛋白基因表达的影响

Study on MRP genetic expression in patients with hepatocellular carcinoma after interventional therapy

目的:研究肝癌介入治疗前后多药耐药相关蛋白基因的表达情况并探讨其临床意义。方法:选择28例不能手术的肝癌患者行TACE治疗,TACE前后对肝癌组织进行细针穿刺活检,再利用实时荧光定量PCR法检测MRP1、MRP2、MRP3和MRP5基因的表达水平,比较TACE治疗前后多药耐药相关蛋白基因的表达情况。结果:28例肝癌患者行TACE治疗后MRP1、MRP3和MRP5基因的表达水平比TACE治疗前表达量明显增高(P<0.05),而MRP2基因的表达水平在TACE治疗前后没有显著性差异(P>0.05)。结论:肝癌患者进行TACE治疗与否不影响MRP2的基因表达,因而肝癌的获得性多药耐药可能与MRP1、MRP3、MRP5基因的表达有关。

Objective：To investigate the differential expressions of gene encoding MRP in hepatocellular carcinoma（HCC） after interventional therapy and its clinical implications.Methods：A total of 28 HCC patients with tumor size≥5 cm were enrolled,which were treated with TACE.Biopsy was performed respectively before and after TACE,and then expression levels of MRP1,MRP2,MRP3,MRP5 mRNAs were detected according to the standard curve using real-time fluorescence quantitative PCR methods.Expression of gene encoding MRP in pretherapy HCC was compared with patients after interventional therapy.Results： After 28 HCC patients were treated with TACE,the expression levels of MRP1,MRP3,MRP5 mRNAs were significantly higher than pre-therapy（P0.05）.The expressions of MRP2 mRNA showed no statistically significant difference between the pre-therapy and post-treatment（P0.05）.Conclusion： After HCC patients were treated with TACE,the expressions of MRP2 mRNA have no effect,and MRP1,MRP3 and MRP5 are related to the acquired drug resistance of hepatocellular carcinoma.